Table 2 Multivariable analysis of non-relapse mortality and overall mortality for daily urinary Na/K ratio.
Non-relapse mortality | Overall mortality | |||
|---|---|---|---|---|
HR (95% CI) | P-value | HR (95% CI) | P-value | |
Landmark at 14 days | ||||
Low daily urinary Na/K ratio at 14 days | 4.82 (1.81–12.83) | 0.001 | 1.59 (0.82–3.07) | 0.163 |
Age ≥ 45 years | 4.71 (1.22–18.16) | 0.024 | 1.64 (0.85–3.17) | 0.135 |
HCT-CI ≥ 3 | 1.10 (0.36–3.33) | 0.859 | 0.84 (0.39–1.80) | 0.666 |
High-risk disease status at CBT | 1.51 (0.54–4.20) | 0.427 | 2.33 (1.25–4.34) | 0.007 |
Cord blood TNC ≥ 2.5 × 107/kg | 0.89 (0.35–2.23) | 0.803 | 0.70 (0.39–1.24) | 0.225 |
HLA disparities ≥ 3 | 1.49 (0.58–3.83) | 0.399 | 1.06 (0.60–1.87) | 0.826 |
Female donor to male recipient | 4.12 (1.54–10.97) | 0.004 | 2.20 (1.23–3.96) | 0.007 |
TBI 2–4 Gy-based regimens | 3.21 (1.05–9.80) | 0.004 | 1.39 (0.68–2.83) | 0.361 |
Landmark at 28 days | ||||
Low daily urinary Na/K ratio at 14 days | 4.47 (1.32–15.12) | 0.015 | 2.38 (1.15–4.91) | 0.018 |
Age ≥ 45 years | 9.03 (1.84–44.38) | 0.006 | 2.16 (1.07–4.36) | 0.030 |
HCT-CI ≥ 3 | 1.57 (0.49–4.97) | 0.441 | 0.91 (0.42–1.96) | 0.819 |
High-risk disease status at CBT | 1.00 (0.36–2.76) | 0.986 | 1.91 (1.03–3.55) | 0.038 |
Cord blood TNC ≥ 2.5 × 107/kg | 0.95 (0.35–2.54) | 0.927 | 0.69 (0.39–1.24) | 0.219 |
HLA disparities ≥ 3 | 1.88 (0.68–5.21) | 0.220 | 1.09 (0.61–1.94) | 0.767 |
Female donor to male recipient | 2.47 (0.90–6.81) | 0.078 | 1.94 (1.08–3.50) | 0.026 |
TBI 2–4 Gy-based regimens | 2.46 (0.77–7.80) | 0.124 | 1.18 (0.56–2.48) | 0.654 |
